Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

April Slee

Showing results (21-30 of 53) with videos related to

Pageof 6
Sort By:
Cardiology in the Young|November 3, 2023
Real-world experience with edoxaban for anticoagulation in children at risk for coronary artery thrombosisEyal Sagiv, David M Newland, April Slee, et al.
Regional Anesthesia and Pain Medicine|February 7, 2015
A standardized anesthetic and surgical clinical pathway for esophageal resection: impact on length of stay and major outcomesGrete H Porteous, Joseph M Neal, April Slee, et al.
Atherosclerosis|June 21, 2016
Relationship of baseline HDL subclasses, small dense LDL and LDL triglyceride to cardiovascular events in the AIM-HIGH clinical trialJohn J Albers, April Slee, Jerome L Fleg, et al.
The American Journal of Cardiology|January 27, 2005
Use of amiodarone for atrial fibrillation in patients with preexisting pulmonary disease in the AFFIRM studyBrian Olshansky, Magdi Sami, Andrew Rubin, et al.
The Journal of Thoracic and Cardiovascular Surgery|June 30, 2012
Triiodothyronine supplementation and cytokines during cardiopulmonary bypass in infants and childrenJames R Priest, April Slee, Aaron K Olson, et al.
Cardiology in the Young|May 12, 2022
Etanercept with IVIg for acute Kawasaki disease: a long-term follow-up on the EATAK trialEyal Sagiv, April Slee, Ashley Buffone, et al.
Diabetes Care|December 1, 2016
The Effect of Canagliflozin, a Sodium Glucose Cotransporter 2 Inhibitor, on Glycemic End Points Assessed by Continuous Glucose Monitoring and Patient-Reported Outcomes Among People With Type 1 DiabetesHelena W Rodbard, Anne L Peters, April Slee, et al.
Value in Health : the Journal of the International Society for Pharmacoeconomics and Outcomes Research|September 15, 2007
Assessing the impact of censoring of costs and effects on health-care decision-making: an example using the Atrial Fibrillation Follow-up Investigation of Rhythm Management (AFFIRM) studyElisabeth Fenwick, Deborah A Marshall, Gordon Blackhouse, et al.
International Journal of Clinical Practice|September 8, 2016
Efficacy and safety of canagliflozin in patients with type 2 diabetes mellitus living in hot climatesMathew John, Sonia Cerdas, Rafael Violante, et al.
Clinical Kidney Journal|July 5, 2021
Effects of canagliflozin on serum potassium in the CANagliflozin cardioVascular Assessment Study (CANVAS) ProgramMatthew R Weir, April Slee, Tao Sun, et al.
Pageof 6

Showing results (21-30 of 53) with videos related to

Sort By:
Pageof 6
Cardiology in the Young|November 3, 2023
Real-world experience with edoxaban for anticoagulation in children at risk for coronary artery thrombosisEyal Sagiv, David M Newland, April Slee, et al.
Regional Anesthesia and Pain Medicine|February 7, 2015
A standardized anesthetic and surgical clinical pathway for esophageal resection: impact on length of stay and major outcomesGrete H Porteous, Joseph M Neal, April Slee, et al.
Atherosclerosis|June 21, 2016
Relationship of baseline HDL subclasses, small dense LDL and LDL triglyceride to cardiovascular events in the AIM-HIGH clinical trialJohn J Albers, April Slee, Jerome L Fleg, et al.
The American Journal of Cardiology|January 27, 2005
Use of amiodarone for atrial fibrillation in patients with preexisting pulmonary disease in the AFFIRM studyBrian Olshansky, Magdi Sami, Andrew Rubin, et al.
The Journal of Thoracic and Cardiovascular Surgery|June 30, 2012
Triiodothyronine supplementation and cytokines during cardiopulmonary bypass in infants and childrenJames R Priest, April Slee, Aaron K Olson, et al.
Cardiology in the Young|May 12, 2022
Etanercept with IVIg for acute Kawasaki disease: a long-term follow-up on the EATAK trialEyal Sagiv, April Slee, Ashley Buffone, et al.
Diabetes Care|December 1, 2016
The Effect of Canagliflozin, a Sodium Glucose Cotransporter 2 Inhibitor, on Glycemic End Points Assessed by Continuous Glucose Monitoring and Patient-Reported Outcomes Among People With Type 1 DiabetesHelena W Rodbard, Anne L Peters, April Slee, et al.
Value in Health : the Journal of the International Society for Pharmacoeconomics and Outcomes Research|September 15, 2007
Assessing the impact of censoring of costs and effects on health-care decision-making: an example using the Atrial Fibrillation Follow-up Investigation of Rhythm Management (AFFIRM) studyElisabeth Fenwick, Deborah A Marshall, Gordon Blackhouse, et al.
International Journal of Clinical Practice|September 8, 2016
Efficacy and safety of canagliflozin in patients with type 2 diabetes mellitus living in hot climatesMathew John, Sonia Cerdas, Rafael Violante, et al.
Clinical Kidney Journal|July 5, 2021
Effects of canagliflozin on serum potassium in the CANagliflozin cardioVascular Assessment Study (CANVAS) ProgramMatthew R Weir, April Slee, Tao Sun, et al.
Pageof 6